Zhitong Finance App News, Conoa-B (02162.HK) announced that the company's key research product CM512 (TSLP/IL-13 double antibody) has been included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration to treat chronic sinusitis with nasal polyps (CRSwnP).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.